We expect Vertex Pharmaceuticals Incorporated VRTX to surpass expectations when it reports third-quarter 2024 results on Nov.

Vertex, Inc. VERX reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance on ...

Vertex, Inc. (NASDAQ:VERX) Q3 2024 Earnings Call Transcript ... If you haven't already done so, please mark your calendars ...

Vertex, Inc. ( (VERX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex, Inc. presented to its investors. Vertex, ...

VRTX to report Q3 earnings, expected EPS $4.14 and $2.72B in revenue. Cramer calls it a buy, analysts see 22% upside. Stock ...

JMP Securities raised the firm’s price target on Vertex (VERX) to $61 from $47 and keeps an Outperform rating on the shares. The company ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of 14 cents per share. The company posted revenue of $170.4 ...

Vertex VERX, a Zacks Rank #1 (Strong Buy), offers enterprise tax technology solutions for retail trade, wholesale trade, and manufacturing industries in the United States and internationally.

Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ETCompany ParticipantsJoe Crivelli - Vice President, ...